id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2013-N-0500-0143,FDA,FDA-2013-N-0500,"03- Reference 02- U.S. Department of Health and Human Services, Food and Drug Administration, “Fiscal Year 2019 Justification of Estimates for Appropriations Committees",Supporting & Related Material,Background Material,2018-12-14T05:00:00Z,2018,12,,,2018-12-14T15:14:01Z,,0,0,09000064839949a4
FDA-2013-N-0500-0141,FDA,FDA-2013-N-0500,01-List of References Withdrawal of Proposed Rule on Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products,Supporting & Related Material,Background Material,2018-12-14T05:00:00Z,2018,12,,,2018-12-14T15:12:24Z,,0,0,09000064839949a2
FDA-2013-N-0500-0140,FDA,FDA-2013-N-0500,"Withdrawal of Proposed Rule on Supplemental Applications Proposing
Labeling Changes for Approved Drugs and Biological Products",Proposed Rule,Withdrawal,2018-12-14T05:00:00Z,2018,12,2018-12-14T05:00:00Z,,2018-12-14T14:36:07Z,2018-27098,0,0,09000064839936bc
FDA-2013-N-0500-0142,FDA,FDA-2013-N-0500,"02- Reference 01- Draft guidance for industry, “Updating ANDA Labeling After the Marketing Application for the Reference Listed Drug Has Been Withdrawn,”",Supporting & Related Material,Background Material,2018-12-14T05:00:00Z,2018,12,,,2018-12-14T15:13:06Z,,0,0,09000064839949a3